iCampus aids growth of biomedical industry in WND

The Wuxi International Life-Science Innovation Campus (iCampus), in Wuxi New District (WND), Wuxi achieved an output of 7.5 billion yuan ($1.06 billion) in 2022, according to Leon Wang, executive vice-president International and China President at AstraZeneca.

iCampus, built by governments of Wuxi and WND and AstraZeneca, is intended to attract biomedical companies to the city. The second phase of the industrial park was put into use on May 19 and construction on its third phase started that same day.

"I think we should deepen cooperation with the local government, as they need industry leaders like us in developing the biomedical sector," Wang added.

Cui Rongguo, Party secretary of WND, said that WND and AstraZeneca will work together to attract high-level technological innovation projects. He noted that AstraZeneca has invested a total of $465 million in Wuxi and established multiple centers and platforms to draw high-quality companies and teams.

WND has been actively developing biomedicine in recent years, and its biomedical parks rank among the top in China. AstraZeneca has played an important role in this, Cui added.